Drug Profile
Famitinib - Jiangsu Hengrui Medicine
Alternative Names: Famitinib maleate; SHR 1020Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Fudan University; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cervical cancer; Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer
- Phase II Biliary cancer; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
- Phase I/II Osteosarcoma
- Clinical Phase Unknown Fibroma
- No development reported Breast cancer
Most Recent Events
- 30 Mar 2024 Second Affiliated Hospital of Xi'an Jiaotong University plans phase-II trial for Non small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in March 2024 (PO), (NCT06336954)
- 09 Feb 2024 Jiangsu HengRui Medicine terminates phase III trial in Gastrointestinal stromal tumours (Inoperable/Unresectable, Late-stage disease) in China (PO) due to R&D business strategy (NCT04409223)
- 01 Feb 2024 Jiangsu Province Nanjing Brain Hospital initiates a phase II trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06332300)